Yes, this is why I said the cancer part has not been given much value. That week of combo results, the share price moved up 50%. But the day of the PR that the fda approved the tnbc trial, the share price actually dropped. So the market is assigning huge value to combo and little value to tnbc so far. That means with good ctc numbers, the market should jump to represent the increased value, which has not been added before. Also, I believe this means a jump with BLA full submission. Now the secondary market, paulson investors, I'm sure the cancer story has helped sell shares, but not so much in the actual market. All in my opinion.